Flex Ltd’s Insider Paul Humphries Unloaded 27,532 Shares of the Company; 2 Analysts Are Bullish Flex Pharma, Inc. (FLKS) Last Week

Flex Ltd. (NASDAQ:FLEX) Logo

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Coverage

Among 3 analysts covering Flex Pharma (NASDAQ:FLKS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Flex Pharma had 5 analyst reports since January 25, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Thursday, March 8 with “Buy”. Ladenburg Thalmann downgraded the shares of FLKS in report on Wednesday, June 13 to “Neutral” rating. The firm has “Buy” rating given on Friday, April 6 by Jefferies. The company was maintained on Tuesday, February 13 by Jefferies. See Flex Pharma, Inc. (NASDAQ:FLKS) latest ratings:

13/06/2018 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Neutral Old Target: $12 Downgrade
06/04/2018 Broker: Jefferies Rating: Buy New Target: $7.0000 Maintain
08/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $40.0 Maintain
13/02/2018 Broker: Jefferies Rating: Buy New Target: $6.0 Maintain
25/01/2018 Broker: Ladenburg Thalmann Rating: Buy New Target: $12 Initiates Coverage On

The stock decreased 3.59% or $0.04 during the last trading session, reaching $0.94. About 193,183 shares traded. Flex Pharma, Inc. (NASDAQ:FLKS) has risen 16.07% since July 1, 2017 and is uptrending. It has outperformed by 3.50% the S&P500. Some Historical FLKS News: 07/03/2018 – Flex Pharma 4Q Loss $8.03M; 26/03/2018 – FLEX PHARMA: FLX-787 INCREASED CRAMP-FREE DAYS; 26/03/2018 – FLEX PHARMA: FLX-787 CUT CRAMP/SPASM FREQUENCY; 07/03/2018 – Flex Pharma: Expect to Report Results From Number of Larger Clinical Trials in Next 12 Months; 26/03/2018 – FLEX PHARMA – FLX-787 REDUCED CRAMP/SPASM FREQUENCY AND INCREASED CRAMP-FREE DAYS IN MS PATIENTS IN PRE-SPECIFIED ANALYSIS OF PARALLEL TREATMENT PHASE; 26/03/2018 – FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS; 19/04/2018 – DJ Flex Pharma Inc, Inst Holders, 1Q 2018 (FLKS); 26/03/2018 – FLEX PHARMA INC – FLX-787 WAS GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED; 07/03/2018 – FLEX PHARMA INC – EXPECTS TO HAVE SUFFICIENT CAPITAL TO FUND ITS OPERATIONS TO MID 2019; 07/03/2018 Flex Pharma Reports Year End 2017 Financial Results

More notable recent Flex Pharma, Inc. (NASDAQ:FLKS) news were published by: Benzinga.com which released: “Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut” on June 13, 2018, also Digitaljournal.com with their article: “FLEX PHARMA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed Against Flex Pharma; Block & Leviton …” published on June 29, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018. More interesting news about Flex Pharma, Inc. (NASDAQ:FLKS) were released by: Globenewswire.com and their article: “SHAREHOLDER ALERT – NWL FLKS: The Law Offices of Vincent Wong Notifies Investors of Important Class Action …” published on June 26, 2018 as well as Globenewswire.com‘s news article titled: “UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NWL …” with publication date: June 28, 2018.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $16.93 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

It was revealed in a legal form submitted to the U.S. SEC that Paul Humphries, who works for Flex Ltd, and currently holds the position of Group President executed an insider trade on June 29, 2018. Paul unloaded 27,532 shares of the corporation estimated based on $14.3 US Dollars per every share. As stated in the electronic form freely available here, the total amount of the trade was $393,551 US Dollars. He also unloaded 99,695 shares worth approximately $1,444,630 USD in the last 30 days. This is a stocks unloading that is not going to stay ignored as Paul already owns 543,001 shares accounting for 0.10% of the Company’s market cap

Among 6 analysts covering Flex Ltd (NASDAQ:FLEX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Flex Ltd has $22.0 highest and $16 lowest target. $18.75’s average target is 32.88% above currents $14.11 stock price. Flex Ltd had 9 analyst reports since January 3, 2018 according to SRatingsIntel. UBS maintained Flex Ltd. (NASDAQ:FLEX) rating on Friday, May 11. UBS has “Buy” rating and $1800 target. Citigroup maintained it with “Buy” rating and $16 target in Monday, April 30 report. The stock of Flex Ltd. (NASDAQ:FLEX) earned “Buy” rating by RBC Capital Markets on Thursday, January 25. RBC Capital Markets maintained Flex Ltd. (NASDAQ:FLEX) on Wednesday, January 3 with “Buy” rating. As per Monday, June 18, the company rating was upgraded by Standpoint Research. The stock of Flex Ltd. (NASDAQ:FLEX) has “Buy” rating given on Thursday, January 25 by Stifel Nicolaus. The firm has “Hold” rating given on Friday, April 27 by Raymond James. The firm has “Buy” rating given on Friday, April 27 by Stifel Nicolaus.

Since February 1, 2018, it had 0 buys, and 8 insider sales for $7.36 million activity. MCNAMARA MICHAEL M had sold 239,288 shares worth $3.47M. Collier Christopher sold $713,459 worth of Flex Ltd. (NASDAQ:FLEX) on Tuesday, June 19. Barbier Francois also sold $739,721 worth of Flex Ltd. (NASDAQ:FLEX) shares. SHIH WILLY C also sold $243,573 worth of Flex Ltd. (NASDAQ:FLEX) on Thursday, February 1. 10,576 shares were sold by Bennett David P, worth $153,309 on Tuesday, June 19. 41,218 shares valued at $597,257 were sold by Britt Douglas on Tuesday, June 19. Shares for $4,567 were sold by Tan Lay Koon on Friday, April 20.

Investors sentiment increased to 1.14 in Q1 2018. Its up 0.33, from 0.81 in 2017Q4. It increased, as 30 investors sold Flex Ltd. shares while 102 reduced holdings. 53 funds opened positions while 97 raised stakes. 488.10 million shares or 2.75% less from 501.93 million shares in 2017Q4 were reported. Birmingham Capital Management Inc Al accumulated 0.26% or 38,150 shares. Mufg Americas Holding Corporation holds 107 shares or 0% of its portfolio. Oppenheimer Asset Mgmt Incorporated holds 0.02% in Flex Ltd. (NASDAQ:FLEX) or 51,132 shares. Wellington Management Gru Llp has invested 0.16% in Flex Ltd. (NASDAQ:FLEX). Contour Asset Lc stated it has 5.59M shares. Pzena Mgmt reported 0.4% of its portfolio in Flex Ltd. (NASDAQ:FLEX). Huntington Bank & Trust holds 1,715 shares or 0% of its portfolio. 91,600 were reported by Quantitative Invest Mngmt Ltd Limited Liability Company. Lowe Brockenbrough Inc, a Virginia-based fund reported 15,750 shares. Fjarde Ap accumulated 210,500 shares. Robeco Institutional Asset Mgmt Bv reported 0.01% in Flex Ltd. (NASDAQ:FLEX). Aviva Public Limited accumulated 658,295 shares or 0.07% of the stock. First Quadrant Ltd Partnership Ca owns 1,042 shares or 0% of their US portfolio. Berson And Corrado Investment Advsrs Lc holds 2.15% or 219,342 shares. Tocqueville Asset Mngmt Lp accumulated 761,000 shares or 0.16% of the stock.

The stock increased 1.22% or $0.17 during the last trading session, reaching $14.11. About 4.18M shares traded. Flex Ltd. (NASDAQ:FLEX) has declined 18.33% since July 1, 2017 and is downtrending. It has underperformed by 30.90% the S&P500. Some Historical FLEX News: 16/05/2018 – Flex Presenting at Bank of America Conference Jun 6; 18/04/2018 – FLEX LNG LTD – TIME CHARTER PERIOD OF 12 MONTHS WILL COMMENCE DURING SECOND HALF OF 2019; ENEL HAS OPTION TO EXTEND CONTRACT BY ADDITIONAL 12 MONTHS; 22/03/2018 – FBO:Veteran Aff: Veterans Affairs Contract Award – 65–Performa Power Flex Treatment Tables – 36C24418Q0370; 09/05/2018 – Hagens Berman Alerts Investors in Flex Ltd. (FLEX) to the July 9, 2018 Securities Class Action Lead Plaintiff Deadline; 29/05/2018 – FLEX LNG LTD FLNG.OL – DECIDED TO APPOINT BOARD MEMBER MARIUS HERMANSEN AS INTERIM CEO; 19/04/2018 – REVERSE FLEX: Ferro $355m TLB-1, $235m TLB-2 Now Offered at Par; 20/03/2018 – FDA: Merit Medical Systems, Inc.- Flex-Neck Classic Peritoneal Dialysis Catheter 1 Cuff Infant Coiled, Catalog # CF-4235/B; 10/04/2018 – AIRBUS GROUP AIR.PA – AIRBUS LAUNCHES NEW CABIN-FLEX OPTION FOR A380 WITH QANTAS; 26/03/2018 – Top Factors Driving the Global Automotive Flex Fuel Engine Market l Technavio; 27/03/2018 – FDA: Johnson & Johnson Consumer, Inc.- Johnson & Johnson BAND-AID® Brand First Aid Products SECURE-FLEX® Wrap (size: 2in)

More recent Flex Ltd. (NASDAQ:FLEX) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT – GOGO INWK FLEX SYMC REPH ORA TAL: The Law Offices of Vincent Wong Reminds ..” on June 28, 2018. Also Globenewswire.com published the news titled: “SHAREHOLDER ALERT – PRTA TAL NWL FLEX HAIR GOGO: The Law Offices of Vincent Wong Reminds Investors of ..” on June 29, 2018. Globenewswire.com‘s news article titled: “Federman & Sherwood Reminds Investors of Imminent Lead Plaintiff Deadline in Securities Class Action Lawsuit ..” with publication date: June 26, 2018 was also an interesting one.

Analysts await Flex Ltd. (NASDAQ:FLEX) to report earnings on July, 26. They expect $0.19 EPS, down 9.52% or $0.02 from last year’s $0.21 per share. FLEX’s profit will be $100.37 million for 18.57 P/E if the $0.19 EPS becomes a reality. After $-0.04 actual EPS reported by Flex Ltd. for the previous quarter, Wall Street now forecasts -575.00% EPS growth.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Chart